From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
Histology | Cytotoxic compounds with selective activity | Target-therapies with selective activities |
---|---|---|
Leiomyosarcoma | Gemcitabine ± docetaxel, trabectedin, dacarbazine | Pazopanib |
Dedifferentiated liposarcoma | High-dose ifosfamide, trabectedin, eribulin | Â |
Myxoid liposarcoma | Trabectedin, eribulin | Â |
Synovial sarcoma | Ifosfamide, trabectedin | Pazopanib |
Epithelioid sarcoma | Gemcitabine | Pazopanib |
Angiosarcoma/intimal sarcoma | Gemcitabine, paclitaxel | Pazopanib, sorafenib |
Alveolar soft part sarcoma | Â | Pazopanib, sunitinib, cedinarib |
Solitary fibrous tumour | Dacarbazine | Pazopanib, sunitinib |
Clear cell sarcoma | Â | Pazopanib, sunitinib |
Extraskeletal myxoid chondrosarcoma | Â | Pazopanib, sunitinib |
Perivascular epithelioid cell tumor | Gemcitabine | m-TOR inhibitors |
Epithelioid hemangioendothelioma | Â | Pazopanib, m-TOR inhibitors, interferon |
Inflammatory myofibroblastic tumour | Â | Crizotinib |
Undifferentiated pleomorphic sarcoma | High-dose ifosfamide, gemcitabine | Â |
Dermatofibrosarcoma protuberans | Â | Imatinib, sorafenib, sunitinib |